BAY 1187982

Drug Profile

BAY 1187982

Alternative Names: BAY1187982; FGFR2-ADC - Bayer

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator Bayer
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 30 Aug 2016 Bayer terminates a phase-I clinical trial in Solid tumours (Late-stage disease, Second-line therapy or greater), in USA, South Korea and Singapore (IV) (NCT02368951)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Germany (IV, Infusion)
  • 01 Mar 2015 Phase-I clinical trials in Solid tumours in USA (Late-stage disease, Second-line therapy or greater), South Korea (Late-stage disease, Second-line therapy or greater) (IV) (NCT02368951)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top